Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pemetrexed + PF-3512676
- Development stage
- Discontinued
- Lead developer
- Pfizer
- Modality
- Small Molecules, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Pemetrexed is a small molecule antifolate antineoplastic agent that inhibits folate-dependent enzymes involved in the synthesis of thymidine and purine nucleotides, thereby disrupting DNA and RNA synthesis essential for cancer cell replication. It is primarily used for the treatment of non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma, often in combination with other chemotherapeutic agents[1][2][5][7]. PF-3512676 (also known as CpG 7909) is a synthetic immunomodulatory oligonucleotide that acts as an agonist of Toll-like receptor 9 (TLR9), stimulating immune responses against tumors[8]. The combination was investigated for advanced NSCLC but clinical development was discontinued after phase III trials showed no additional efficacy over standard chemotherapy alone[6].
- Brand names
- AlimtaPemfexy
- Other names
- pemetrexed disodiumCpG 7909CpG7909CpG-7909
02
Targets
GART (GAR transformylase)TLR9 (Toll-like receptor 9)DHFR (Dihydrofolate reductase)TS (Thymidylate synthase)
Beyond the preview
Go deeper on pemetrexed + PF-3512676.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pemetrexed + PF-3512676.